Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Aug;62(2):309–313. doi: 10.1038/bjc.1990.284

4-hydroxyandrostenedione--further clinical and extended endocrine observations.

T Pickles 1, L Perry 1, P Murray 1, P Plowman 1
PMCID: PMC1971820  PMID: 2386749

Abstract

4-Hydroxyandrostenedione (4-OHA) was administered (250 mg intramuscularly 2-weekly) in a phase 2 clinical trial to 20 postmenopausal patients with advanced breast cancer, who had failed other endocrine therapy. Seven out of 18 assessable patients (39%) responded with minimal toxicity. Endocrine studies demonstrated that the drug produced significant initial falls in oestradiol and oestrone levels, but that these levels rose toward pretreatment levels as the study progressed. Sex hormone binding globulin (SHBG) levels gradually fell during the study suggesting that the drug has a minor degree of androgenic activity albeit of no clinical significance. There was a transient reduction of adrenal steroid levels, which remained however within the normal range. There were no symptoms of adrenal insufficiency.

Full text

PDF
309

Images in this article

311Figure 1
on p.311

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brodie A. M., Coombes R. C., Dowsett M. Aromatase inhibitors: basic and clinical studies. J Steroid Biochem. 1987;27(4-6):899–903. doi: 10.1016/0022-4731(87)90166-x. [DOI] [PubMed] [Google Scholar]
  2. Brodie A. M., Schwarzel W. C., Shaikh A. A., Brodie H. J. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology. 1977 Jun;100(6):1684–1695. doi: 10.1210/endo-100-6-1684. [DOI] [PubMed] [Google Scholar]
  3. Coombes R. C., Goss P., Dowsett M., Gazet J. C., Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 1984 Dec 1;2(8414):1237–1239. doi: 10.1016/s0140-6736(84)92795-8. [DOI] [PubMed] [Google Scholar]
  4. Cunnah D., Jessop D. S., Besser G. M., Rees L. H. Measurement of circulating corticotrophin-releasing factor in man. J Endocrinol. 1987 Apr;113(1):123–131. doi: 10.1677/joe.0.1130123. [DOI] [PubMed] [Google Scholar]
  5. Cunningham D., Powles T. J., Dowsett M., Hutchison G., Brodie A. M., Ford H. T., Gazet J. C., Coombes R. C. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother Pharmacol. 1987;20(3):253–255. doi: 10.1007/BF00570496. [DOI] [PubMed] [Google Scholar]
  6. Dowsett M., Cunningham D. C., Stein R. C., Evans S., Dehennin L., Hedley A., Coombes R. C. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 1989 Mar 1;49(5):1306–1312. [PubMed] [Google Scholar]
  7. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
  8. Fattah D. I., Chard T. Simplified method for measuring sex-hormone binding globulin. Clin Chem. 1981 Jul;27(7):1277–1279. [PubMed] [Google Scholar]
  9. Goss P. E., Powles T. J., Dowsett M., Hutchison G., Brodie A. M., Gazet J. C., Coombes R. C. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res. 1986 Sep;46(9):4823–4826. [PubMed] [Google Scholar]
  10. Holly J. M., Smith C. P., Dunger D. B., Howell R. J., Chard T., Perry L. A., Savage M. O., Cianfarani S., Rees L. H., Wass J. A. Relationship between the pubertal fall in sex hormone binding globulin and insulin-like growth factor binding protein-I. A synchronized approach to pubertal development? Clin Endocrinol (Oxf) 1989 Sep;31(3):277–284. doi: 10.1111/j.1365-2265.1989.tb01251.x. [DOI] [PubMed] [Google Scholar]
  11. Murray R., Pitt P. Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol. 1985 Jan;21(1):19–22. doi: 10.1016/0277-5379(85)90195-6. [DOI] [PubMed] [Google Scholar]
  12. Perry L. A., Al-Dujaili E. A., Edwards C. R. A direct radioimmunoassay for 11-deoxycortisol. Steroids. 1982 Feb;39(2):115–128. doi: 10.1016/0039-128x(82)90080-0. [DOI] [PubMed] [Google Scholar]
  13. Perry L. A., Wathen N., Chard T. Saliva levels of oestradiol and progesterone in relation to non-protein-bound concentrations in blood during late pregnancy. Horm Metab Res. 1987 Sep;19(9):444–447. doi: 10.1055/s-2007-1011848. [DOI] [PubMed] [Google Scholar]
  14. Reiffsteck A., Dehennin L., Scholler R. Estrogens in seminal plasma of human and animal species: identification and quantitative estimation by gas chromatography-mass spectrometry associated with stable isotope dilution. J Steroid Biochem. 1982 Nov;17(5):567–572. doi: 10.1016/0022-4731(82)90017-6. [DOI] [PubMed] [Google Scholar]
  15. Rowell N. P., Gilmore O. J., Plowman P. N. Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity. Hum Toxicol. 1987 May;6(3):227–232. doi: 10.1177/096032718700600310. [DOI] [PubMed] [Google Scholar]
  16. Vincent M. D., Clink H. M., Coombes R. C., Smith I. E., Kandler R., Powles T. J. Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer. Br Med J (Clin Res Ed) 1985 Jul 13;291(6488):105–106. doi: 10.1136/bmj.291.6488.105-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wathen N. C., Perry L. A., Rubenstein E., Chard T. A relationship between sex hormone binding globulin and dehydroepiandrosterone sulfate in normally menstruating females. Gynecol Endocrinol. 1987 Mar;1(1):47–50. doi: 10.3109/09513598709082695. [DOI] [PubMed] [Google Scholar]
  18. Wathen N. C., Perry L., Lilford R. J., Chard T. Interpretation of single progesterone measurement in diagnosis of anovulation and defective luteal phase: observations on analysis of the normal range. Br Med J (Clin Res Ed) 1984 Jan 7;288(6410):7–9. doi: 10.1136/bmj.288.6410.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Young J. A., Newcomer L. N., Keller A. M. Aminoglutethimide-induced bone marrow injury. Report of a case and review of the literature. Cancer. 1984 Oct 15;54(8):1731–1733. doi: 10.1002/1097-0142(19841015)54:8<1731::aid-cncr2820540842>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES